The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations
- 29 June 2006
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 7 (10) , 1399-1407
- https://doi.org/10.1517/14656566.7.10.1399
Abstract
(2006). The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations. Expert Opinion on Pharmacotherapy: Vol. 7, No. 10, pp. 1399-1407. doi: 10.1517/14656566.7.10.1399Keywords
This publication has 65 references indexed in Scilit:
- The ‘magic’ of -dopa: why is it the gold standard Parkinson's disease therapy?Trends in Pharmacological Sciences, 2005
- “Levodopa phobia”: A new iatrogenic cause of disability in Parkinson diseaseNeurology, 2005
- Levodopa and the Progression of Parkinson's DiseaseNew England Journal of Medicine, 2004
- Levodopa in the treatment of Parkinson's disease: Current controversiesMovement Disorders, 2004
- Long‐duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half‐lifeMovement Disorders, 2001
- Dyskinesias and motor fluctuations in Parkinson's diseaseBrain, 2000
- Continuous dopamine-receptor stimulation in early Parkinson's diseaseTrends in Neurosciences, 2000
- Endothelin-1 in the brain of patients with galactosialidosis: Its abnormal increase and distribution patternAnnals of Neurology, 2000
- Levodopa therapy and survival in idiopathic Parkinson's diseaseNeurology, 1993
- Aromatic Amino Acids and Modification of ParkinsonismNew England Journal of Medicine, 1967